Stock Ratings / Health Care / INFU / forecast

ANIK (55) OSUR (32) TMCI (41) CLPT (34) ⌘ Pro Terminal →

InfuSystems Holdings Inc. (INFU) 12-Month Stock Forecast & Price Target Cone

$14.45 +0.91% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $14.51

InfuSystems Holdings Inc. (INFU) earns a Roarable Rating of B+ (Buy) with 76/100 RQD Confidence. High-quality cash engine (56% profit margin, 13% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

📊 Historical Track Record: Scores of 76/100 (B+) historically ranked in the Top 11% of excess returns over the next 90 days (+7.6% avg 90D alpha vs SPY • 70.0% hit rate) →

ROARABLE B+ • BUY Cap $287.8M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $14.51 (+0.40%)🧬 Cannibal Buyback (-2.08% YoY Shares)⚙️ Cash Engine: 14/20 (B-) • 16.6% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 76/100 (B+) historically ranked in the Top 11% of excess returns over the next 90 days (+7.6% avg 90D alpha vs SPY • 70.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERBUY • B+

3-of-3 JEV AI Jury Bullish

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw C+ · Rk A

Each axis scored 0–20

12M PRICE TARGET CONE+8.1% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for INFU)Realized 20D OHLCV Swing Band: ±7.8%

Deterministic 5-Pillar Attribution (76/100 Composite)

🔍 WHY INFU SCORES 76/100 (B+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+18/20 pts (24% of score)

Altman Z-Score 5.16 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 9/9

▲ #2 Bullish Driver: Macro Regime Fit+18/20 pts (24% of score)

FRED Regime × Technicals: 97% of 52W Range • RSI-14 at 58.6 (BULLISH MOMENTUM)

▼ #1 Drag / Risk Factor: Whale & Options Positioning11/20 pts (-9 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-9 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade B-$13.56-1.2% Next Q

Q2 (-2Q)

Grade B$13.40+4% Next Q

Q3 (-1Q)

Grade B$13.94+3.7% Next Q

Current

Grade B+$14.45+7.6% Hist 90D α

Trajectory: B- (68) → B+ (76)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the INFU Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 76/100 (B+) score, INFU faces multiple-compression risk if 43.4x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Priced at 43x earnings—high expectations leave less room for a lukewarm quarter.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-2.08% YoY Shares) — any gross margin slip below 53.5% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($12.97) or 200D SMA ($10.33) invalidates the momentum regime and cuts Target Base ($15.62) toward Bear Floor ($11.85).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $INFU• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “INFU Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 76%NO 24%Trade / Inspect Odds →

INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your INFU Position Size: $10,000

Shares at $14.45: 692.0 sh

$1,000$10,000$25,000$50,000$100,000

12M Bear Case FloorTarget $11.85

$8,201

$-1,799 (-18.0%)

12M Consensus BaseTarget $15.62

$10,810

+$810 (+8.1%)

12M Bull Case BreakoutTarget $18.43

$12,754

+$2,754 (+27.5%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (43 Desks)

Street Historical Accuracy: 64/100

● Strong Buy / Buy: 32● Hold: 9● Sell: 2

Wall Street Firm	Stance	12M Target	1Y Accuracy	Track Grade
Morgan StanleyInstitutional Equity Desk	OUTPERFORM	$16	74%	A
Goldman SachsSector Coverage Lead	STRONG BUY	$17	69%	B
JP MorganUS Large-Cap Research	HOLD	$14	58%	C

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (INFU Tape Review)

✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
✓Forensic Red-Light accounting & dilution traps to review on your watchlist
✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

INFU // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +42.65%▲ ASCENDING CHANNEL

2026-10-30O $14.45H $14.59L $13.92C $14.45VOL 130.3K

RES: $15.20SUP: $9.72SMA50: $12.97SMA200: $10.33

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

INFU Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 INFU Butterfly Map → + Track INFU →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

32.6%/yr Implied 5Y Growth

vs. +6.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on INFU today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for INFU. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for INFU today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (INFU)

Health Care Rank #36 of 1016 ⚔️ ANIK vs INFU Full Matrix →

1. Head-to-Head Health Care Peer Comparison (INFU vs. ANIK, OSUR, TMCI, CLPT)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, InfuSystems Holdings Inc. (INFU) ranks #36 by composite RQD confidence (76/100, grade B+) and #525 by equity capitalization ($287.8M). Within this direct 5-issuer industry benchmark cohort, INFU leads on earnings valuation at 43.4x trailing P/E, while INFU leads on capital efficiency and profitability with 12.8% ROIC and 56.0% gross margin. INFU currently leads its immediate peer cohort in composite quantitative strength at 76/100 (B+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
INFU ACTIVE InfuSystems Holdings Inc.	B+	76/100	43.4x	56.0%	12.8%	+0.91%	$287.8M	Benchmark Subject
ANIK Anika Therapeutics Inc.	D+	55/100	—	56.6%	-10.2%	+1.11%	$291.6M	/anik-vs-infu →
OSUR OraSure Technologies Inc.	E	32/100	—	41.9%	-35.0%	-0.49%	$281.4M	/osur-vs-infu →
TMCI Treace Medical Concepts Inc.	D-	41/100	—	79.8%	-32.4%	+4.76%	$329.1M	/tmci-vs-infu →
CLPT ClearPoint Neuro Inc.	E	34/100	—	61.4%	-35.0%	+1.23%	$342.7M	/clpt-vs-infu →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001337013

In its most recent audited fiscal period (FY2025, filed 2025-12-31), InfuSystems Holdings Inc. (INFU) reported GAAP revenue of $143.4M (+6.4% vs. FY2024 revenue of $134.9M , and +14.0% cumulative change since FY2023) , GAAP net income of $6.6M, operating cash flow of $24.4M, and free cash flow of $23.8M (+23.1% YoY). On the balance sheet, INFU closed FY2025 with $100.6M in total assets against $19.6M in total debt (Altman Z-Score: 5.16, Piotroski F-Score: 9/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$143.4M	$6.6M	$24.4M	$23.8M	$100.6M	$19.6M
FY2024 (FY)	2024-12-31	$134.9M	$2.3M	$20.5M	$19.4M	$103.6M	$23.9M
FY2023 (FY)	2023-12-31	$125.8M	$872.0K	$11.2M	$11.2M	—	—

3. INFU Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is INFU stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, InfuSystems Holdings Inc. (NYSE: INFU) is rated B+ (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 76/100 at a spot price of $14.45 (+0.91% 1D, market cap $287.8M). Pillar breakdown: Fundamental Cash Engine 14/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 18/20, FRED Macro Regime Fit 18/20, and SEC Balance-Sheet Forensics 15/20. Across 1016 tracked Health Care issuers, INFU ranks #36 in composite RQD confidence.

How does INFU compare to ANIK and OSUR in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), INFU carries a Roarable B+ (76/100 RQD), trailing P/E of 43.4x, gross margin of 56.0%, and ROIC of 12.8%. By comparison, ANIK (Anika Therapeutics Inc.) holds a D+ grade (55/100 RQD, P/E N/A, ROIC -10.2%, cap $291.6M) and OSUR (OraSure Technologies Inc.) posts a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $281.4M). Among the 5-stock peer group, INFU leads on earnings multiple (43.4x) while INFU leads on capital efficiency (12.8% ROIC).

What are the biggest fundamental strengths and SEC risk factors for INFU?

Per INFU's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001337013), InfuSystems Holdings Inc. generated $143.4M in revenue (+6.4% YoY), $6.6M in net income, and $23.8M in free cash flow against $100.6M in total assets and $19.6M in total debt. Key quantitative strengths: Company leadership has skin in the game with net positive insider conviction.. Primary risk factors monitored: Priced at 43x earnings—high expectations leave less room for a lukewarm quarter.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is INFU trading relative to its 50-day, 200-day, and 52-week technical levels?

INFU last traded at $14.45 (+0.91% on volume of 74,910 shares), positioning the stock +11.41% above its 50-day simple moving average ($12.97) and +39.88% above its 200-day simple moving average ($10.33). Across its 52-week range of $7.29 to $14.64, INFU sits at the 97.4% percentile with a 14-day RSI of 58.6 (BULLISH MOMENTUM) and an implied next-earnings move of ±7.8% ($13.32 to $15.58).

INFU Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is INFU's 12-month stock price target?

InfuSystems Holdings Inc. (INFU) carries a 12-month consensus base price target of $15.62 (+8.1% from $14.45), with a bull-case target of $18.43 and a bear-case floor of $11.85.

Is INFU stock a Buy, Hold, or Sell right now?

Roarable's 5-Pillar RQD Quant Engine rates INFU B+ (Buy — BUY) with an RQD Confidence score of 76/100.

Direct Sub-Reports: INFU RQD Cockpit INFU 12M Forecast INFU Earnings & Move INFU Dividends & DRIP INFU Insiders & 13F INFU Whale Options INFU Profit Sankey INFU News & Why